APA (7th ed.) Citation

R, S., R, G., K, K., M, W., KS, G., K, B., . . . M, H. (2025). A novel prognostic risk model for patients with refractory/relapsed acute myeloid leukemia receiving venetoclax plus hypomethylating agents. Leukemia, 39(3), 614. https://doi.org/10.1038/s41375-024-02501-6

Chicago Style (17th ed.) Citation

R, Shahswar, et al. "A Novel Prognostic Risk Model for Patients with Refractory/relapsed Acute Myeloid Leukemia Receiving Venetoclax Plus Hypomethylating Agents." Leukemia 39, no. 3 (2025): 614. https://doi.org/10.1038/s41375-024-02501-6.

MLA (9th ed.) Citation

R, Shahswar, et al. "A Novel Prognostic Risk Model for Patients with Refractory/relapsed Acute Myeloid Leukemia Receiving Venetoclax Plus Hypomethylating Agents." Leukemia, vol. 39, no. 3, 2025, p. 614, https://doi.org/10.1038/s41375-024-02501-6.